A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours - Wikidata - awgldk - TriplyDB

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

http://www.wikidata.org/entity/Q35949539

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer A place for precision medicine in bladder cancer: targeting the FGFRs.Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.Multikinase inhibitors use in differentiated thyroid carcinoma.Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants Lenvatinib and Palbociclib.Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer Metastatic melanoma - a review of current and future drugs A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Lenvatinib: first global approval.Drug safety evaluation of lenvatinib for thyroid cancer.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.Efficacy of lenvatinib in treating thyroid cancer.Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

P2860

Q26751274-2A56A6F4-17F2-41B1-9B08-7EE8E254C479 Q26774478-392593BE-6977-4029-9300-E308E3F014EF Q26821959-42934090-BD5D-4B48-A452-FB860BA75B86 Q28072655-7CC9EF86-65CD-40EE-B76F-36983AF9988A Q30249143-7BDEC426-7CC1-4CBE-8C2F-AA0F355D9C3C Q30249385-788E78FA-D948-459C-94AB-244A1408CE77 Q33409140-2C166235-BC36-4BCD-8328-3A2FC46A84CC Q33427289-DA04D7FD-E533-45F6-9DA3-D1BB4B569DE0 Q33433315-5A3BAD52-2606-4B85-AF62-7D3E38DBDC56 Q33607412-03C831F3-91A0-45E3-B3C4-E3BD926DFC81 Q34085125-B119FAA4-8F3E-41D5-B650-7B3350257F56 Q34144848-6A579F3E-09CB-41C9-9CE3-69BF19DBE787 Q34253418-67061659-4515-4D1C-9299-1929BCFAE062 Q34468729-65347802-00FF-4D2B-BDEE-FD9407E9B7FE Q34558883-509335C6-4BA8-44D8-AACB-2F265E550412 Q34660901-FF503C7B-9934-426D-97B5-831BEEE4F3EB Q35144490-9D1736BC-D113-4D75-938E-DF17C9686375 Q35439387-00F4CE94-BB81-445B-A032-2E7C816F810D Q35741930-B00BD2AE-2850-4646-AA59-91F67CED294E Q36109982-2ACE966D-2B9C-48E2-8950-0FE76BDA02F7 Q36619146-A6C1F989-0896-496F-8313-7CF79A112CBB Q36716739-4CB5F4EA-3B18-4B95-99FC-7F03EC2B944E Q36825455-1AD7794A-4A5B-44BC-BD2F-E02DDE31A009 Q36924717-16C7DE05-5500-4093-BAFF-6F8DA53D548E Q37450733-4E82C55C-BDE0-4674-8F9C-CA16860AC46B Q37470131-C24E5C4F-C134-47BD-959C-AD9875C32571 Q37620907-3BFF8685-39A0-46A2-AF22-64705D7C08F8 Q37710134-76C24C6F-EB1B-48F2-BC80-40985C0563F5 Q38185688-36AD3B24-E294-454B-A62E-B7B9BF6707C1 Q38385844-688A9671-5D92-483A-A027-0AA4694E2005 Q38612008-67824104-77D6-4E31-8CE8-D24ABF8E8F6E Q38690050-32A40C3D-1DDA-4A1D-BA49-2F36C1C98956 Q38702994-0E67C9D6-C056-411B-A868-E0FA404B5626 Q38754388-1669D344-F5C2-4686-B3D2-8116EF8EE9A9 Q38754614-406671C7-EC0A-4E9D-BA5D-6E85006EB7E7 Q38843403-1E674CF5-984F-4967-AD99-B5E61CF79BBB Q38995525-8F270EFA-3AE7-467F-A91F-4D93C34B9DE7 Q39011379-ED6888F5-F44A-4B19-9EE7-A8DC915E44C8 Q39442851-A7A0CC79-89ED-4136-A362-F0FDADF31A2E Q40990450-D3B85512-C541-4E29-BB4A-FD87094D5FE4

P2860

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

http://www.wikidata.org/entity/Q35949539

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@ast

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@en

type

label

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@ast

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@en

prefLabel

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@ast

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@en

P1433

Q35949539-E79DAAD1-DC87-4CF6-97EB-2B6DDC2D8F4E

P1476

Q35949539-869575C4-B788-4D2E-AD11-296BEFE40A0E

P2093

Q35949539-10F93575-44AE-4FAE-804D-D0CCF87AFA4D

Q35949539-460DEE9E-CB0B-43EB-84BE-DA772A330A17

Q35949539-51F73177-71F7-4ABF-9E0C-5FBC124137E0

Q35949539-55BC2ACF-1078-45BF-8CF8-56AD40447BD3

Q35949539-74513A01-3B3D-4A63-BD1E-8FD9E838C9A7

Q35949539-82DA6C42-D4C2-4A05-BC78-E18E8243DEA0

Q35949539-87915EDF-07F8-4C1D-9515-4A05F2F59937

Q35949539-A4C26695-1EBC-417A-9C86-09E18DDE614B

Q35949539-B5FCC059-78DC-4BAF-B043-B6AC1C91D00F

Q35949539-B990471E-736D-4FBD-B505-AC0287774302

P2860

Q35949539-09E94ADF-F034-4936-B4E9-FD9916D579DF

Q35949539-0C2817B0-79B0-49D9-B629-9AC5855EE659

Q35949539-137946A9-5137-4CFA-9B19-AA4A53C46F08

Q35949539-142329F9-42D3-4EA1-8234-58793DDD1A72

Q35949539-2031E746-6E44-4BAF-9695-FAE4B7C5B347

Q35949539-214C397F-9B8B-481D-862B-5D8B17EE120B

Q35949539-2193DEF8-818F-472A-9A71-143E4C0B2CC0

Q35949539-221A476F-2FEC-4E16-8BF1-ECEC3E81FE23

Q35949539-24CA0AA1-C997-4F8F-99C2-39DC5A2A3692

Q35949539-2B384344-B0C7-4A10-9C69-66EBD80C6427

P2888

Q35949539-2A7FFB2E-C469-4BBA-BB67-50D2C076ADB2

P304

Q35949539-57AE0B95-FB9D-45C2-AF63-18381502E108

P31

Q35949539-3788978E-C781-4059-9F61-B0A46592A474

P356

Q35949539-C0003C27-63DF-4EA9-8C8D-EBF876C660D8

P407

Q35949539-BD60D354-AF8F-4C6C-ADA4-5A3452E962CB

P433

Q35949539-D7398CF7-899C-475C-A0B7-19B3722990CC

P478

Q35949539-D23931F2-7480-4CF9-A49F-BA72DC5269B6

P577

Q35949539-B4073024-2EC2-4443-9BDF-899A6639B14C

P5875

Q35949539-BC57B9D8-94D9-41E9-A6AC-FEDD6ED90DEA

P698

Q35949539-615609E2-23A2-4EFE-8DD3-F000618E8701

P932

Q35949539-80E34839-5A81-4548-ACA8-64699FA64421

P356

P1433

British Journal of Cancer

P1476

A phase I study of E7080, a mu ...... ts with advanced solid tumours

@en

P2093

A Mazur

http://www.w3.org/2001/XMLSchema#string

B Tait

http://www.w3.org/2001/XMLSchema#string

D S Boss

http://www.w3.org/2001/XMLSchema#string

H Glen

http://www.w3.org/2001/XMLSchema#string

J H Beijnen

http://www.w3.org/2001/XMLSchema#string

J H M Schellens

http://www.w3.org/2001/XMLSchema#string

J P O'Brien

http://www.w3.org/2001/XMLSchema#string

J Wanders

http://www.w3.org/2001/XMLSchema#string

M Keesen

http://www.w3.org/2001/XMLSchema#string

R Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Sunitinib therapy for melanoma patients with KIT mutations.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A quantitative analysis of kinase inhibitor selectivity

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

P2888

P304

1598-1604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.154

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224769415

http://www.w3.org/2001/XMLSchema#string

P698

22516948

http://www.w3.org/2001/XMLSchema#string

P932

3349182

http://www.w3.org/2001/XMLSchema#string